Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. reports developments as a clinical-stage siRNA biopharmaceutical company advancing its proprietary INTASYL® gene-silencing technology for immuno-oncology. Company updates center on PH-762, an INTASYL compound designed to silence the PD-1 gene and evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
Recurring news themes include PH-762 clinical results, safety and pathology data, nonclinical toxicology work, cGMP clinical-supply manufacturing, regulatory-development steps, financial results, equity financing activity and investor presentations. Coverage also reflects the company's use of self-delivering RNAi technology intended to enhance immune-cell activity against tumor cells without specialized formulation or delivery systems.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company, announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The company, known for developing therapeutics using INTASYL® siRNA gene silencing technology to enhance immune cells' cancer-fighting capabilities, will have CEO and Chairman Robert Bitterman present on Tuesday, December 10, 2024, at 12:00 pm EST. Stakeholders and investors are invited to attend this live virtual event, with a replay available on Renmark Financial Communications' website.
Phio Pharmaceuticals (NASDAQ: PHIO) has completed enrollment for the second cohort in its PH-762 Phase 1b dose-escalating clinical trial and added a sixth clinical site in San Diego. New data from the trial shows promising results, with one patient achieving complete response (100% tumor clearance) and another achieving partial response (90% tumor clearance) in the second dose cohort. The study evaluates PH-762, an INTASYL compound that silences PD-1, in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma.
Phio Pharmaceuticals (NASDAQ: PHIO) reported Q3 2024 financial results and provided updates on its Phase 1b clinical trial for PH-762. The trial's second cohort is fully enrolled, showing promising early results with one complete response (100% tumor clearance) and one partial response (90% tumor clearance) in cutaneous squamous cell carcinoma patients. Financial highlights include cash position of $5.4 million as of September 30, 2024, reduced R&D expenses of $0.6 million (down 64% YoY), and a narrowed net loss of $1.5 million compared to $2.8 million in Q3 2023. The company raised approximately $2.6 million through warrant exercises in July 2024.
Phio Pharmaceuticals (NASDAQ: PHIO) announced new clinical data presentation from its ongoing Phase 1b trial at the 39th Annual SITC Meeting. The trial evaluates PH-762 through intratumoral injection in patients with various skin cancers. Results show the treatment has been well-tolerated with no adverse events across five patients in Cohorts 1 and 2.
Notable outcomes include one complete response (100% tumor clearance) and one partial response (90% tumor clearance) in patients with cutaneous squamous cell carcinoma in the second cohort. The trial, expected to complete enrollment by Q3 2025, demonstrates promising results in making immune cells more effective at killing cancer cells using INTASYL® siRNA technology.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company, announces its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The company, known for its INTASYL® siRNA gene silencing technology aimed at enhancing immune cells' cancer-fighting capabilities, will have CEO and Board Chairman Robert Bitterman present on Thursday, November 7 at 12:00 pm EST.
Stakeholders and investors are invited to attend this live virtual event, with a replay available on Renmark Financial Communications' website. The presentation focuses on Phio's innovative approach to creating new pathways towards a cancer-free future through their proprietary technology.
Phio Pharmaceuticals (NASDAQ: PHIO) has announced it will present new clinical data from its ongoing Phase 1b trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, TX from November 8-10, 2024. The presentation, titled 'INTASYL PH-762: PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinoma,' will be delivered by Dr. Mary Spellman on November 9, 2024. The company's proprietary INTASYL siRNA gene silencing technology is designed to enhance immune cells' effectiveness in killing tumor cells.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company, has announced a correction to the registration link for their upcoming presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The event, featuring CEO and Chairman Robert Bitterman, is scheduled for Wednesday, October 23, 2024, at 12 PM EDT.
Stakeholders, investors, and other interested parties are invited to register and attend this live event. The presentation will include a live Q&A session. A replay of the event will be available on the Renmark Financial Communications Inc. website. Phio Pharmaceuticals specializes in INTASYL® siRNA gene silencing technology, designed to enhance immune cells' effectiveness in killing tumor cells.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company, has announced its participation in the Renmark Financial Communications Virtual Non-deal Roadshow Series. The event will feature a presentation and live Q&A session on Wednesday, October 23, 2024, at 12 PM EDT.
Mr. Robert Bitterman, CEO and Chairman of the Board, will lead the presentation. Phio Pharmaceuticals specializes in INTASYL® siRNA gene silencing technology, designed to enhance immune cells' effectiveness in killing tumor cells.
Stakeholders, investors, and interested individuals are invited to register and attend this live event. A replay will be available on the Renmark Financial Communications Inc. website. To ensure smooth connectivity, attendees are advised to use the latest version of Google Chrome when accessing the registration link.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is presenting data on its INTASYL compound PH-894 at the ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer conference. The presentation focuses on how PH-894 improves the functionality and cytotoxicity of Natural Killer (NK) cells in fighting cancer:
1. PH-894 leads to potent and specific silencing of BRD4 in NK cells without affecting cell viability.
2. It boosts NK cell numbers by enhancing proliferation during ex vivo expansion.
3. PH-894 decreases expression of CD94, an inhibitory receptor, potentially improving cytotoxic potential.
4. It may improve NK cell efficacy in adoptive cell therapies.
5. PH-894 serves as a foundation for future NK cell-based immunotherapies.
The presentation by Melissa Maxwell is scheduled for October 16, 2024, from 8 a.m. to 6:45 p.m. ET in the FDR Ballroom.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced data showcasing its proprietary INTASYL platform and compounds. INTASYL offers precise targeting by silencing mRNA both intracellularly and extracellularly, enhancing immune responses against cancer. The technology is effective as intratumoral injections and during immune cell expansion for adoptive cell therapy, requiring no special formulations for siRNA delivery.
Key INTASYL compounds include:
- PH-762: Silences PD-1, improving therapeutic efficacy in vivo
- PH-894: Silences BRD4, enhancing tumor cell immunogenicity and inducing apoptosis
- PH-804: Silences TIGIT in NK cells, enhancing activation, cytokine release, and target cell killing
- PH-905: Silences CBLB, increasing NK cell cytotoxicity and proliferation
The data will be presented at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting in Montreal on October 8th.